Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490352 | 0.90 | ADRB1 (0.56) | ADRB1ADRB3 | |
| SCHEMBL6490353 | 0.90 | ADRB1 (0.56) | ADRB1ADRB3 | |
| SCHEMBL6479638 | 0.89 | ADRB3 (0.49) | ADRB1ADRB3CASRALDH1A1POLB | |
| SCHEMBL6489743 | 0.88 | ADRB3 (0.46) | ADRB1ADRB3CASRALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL6479235 | 0.88 | ADRB1 (0.46) | ADRB1ADRB3CASRALDH1A1POLB | |
| SCHEMBL7689127 | 0.88 | ADRB3 (0.47) | ADRB1ADRB3CASRALDH1A1POLB | |
| SCHEMBL6486808 | 0.84 | CYP1A2 (0.42) | ADRB1ADRB3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6489074 | 0.79 | ADRB1 (0.60) | ADRB1ADRB3ALDH1A1 | |
| Oxalic Acid SCHEMBL6479254 | 0.79 | ADRB3 (0.54) | ADRB1ADRB3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6489063 | 0.78 | ADRB1 (0.58) | ADRB1ADRB3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | ADRB1 1/4885ADRB3 3/4885CYP1A2 167/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | ADRB1 2/4885ADRB3 3/4885CYP1A2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.